Mumbai, November 30, 2017: Pharma Major, Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Candesartan Cilexetil and Hydrochlorothiazide Tablets USP in the strengths of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg.
The drug combines an angiotensin II receptor (type ATI) antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure (hypertension),company said in afiling with BSE.
Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
United News of India
Hyderabad, November 22, 2024: CARE Hospitals, Nampally, successfully hosted the 12th National Infection Prevention and Control (IPC)…
Bengaluru, November 22, 2024: Fortis Hospital, Cunningham Road successfully performed a life-enhancing robot-assisted kidney transplant on 61-year-old…
By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital …
Kurnool, November 20, 2024: Adoni, Andhra Pradesh, – The Khazi India Foundation is pleased to…
New Delhi, November 20, 2024: Aakash Healthcare marked this year’s Children’s Day with a joyful…